Use of an antibody drug conjugate and a PD-1 inhibitor brings complementary mechanisms together while eliminating the most toxic agent that has been used in combinations to treat classic Hodgkin lymphoma (cHL).
Brentuximab vedotin with nivolumab and standard chemotherapy agents produced a nearly 100% overall response rate in patents with early-stage classical Hodgkin lymphoma.
- Frontline Treatment with ADCETRIS in Combination with Nivolumab, Doxorubicin and Dacarbazine (AN+AD) Shows a Complete Response Rate of 88%, Overall Response Rate of 93% and Favorable Safety Profile
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Affimed Reports 2020 Financial Results and Highlights Recent Operational Progress
Affimed N.V.April 15, 2021 GMT
AFM13 monotherapy: Reported positive data from the preplanned interim analysis for the registration-directed trial in PTCL
AFM13 combination with NK cells: Announced 100% objective response rate in four response evaluable patients, including 2 complete responses
AFM24 monotherapy: AFM24 (phase 1/2a study) completed cohort 4 and is enrolling and treating patients in cohort 5; expansion cohorts expected to start in the second half of 2021
AFM24 combination with NK cells: IND application cleared by the FDA for the combination of AFM24 with NKGen Biotech’s SNK-01 NK autologous cell therapy